199 related articles for article (PubMed ID: 32865782)
1. Development of Antisense Oligonucleotide Gapmers for the Treatment of Huntington's Disease.
Aslesh T; Yokota T
Methods Mol Biol; 2020; 2176():57-67. PubMed ID: 32865782
[TBL] [Abstract][Full Text] [Related]
2. Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy.
Aslesh T; Yokota T
Methods Mol Biol; 2020; 2176():69-85. PubMed ID: 32865783
[TBL] [Abstract][Full Text] [Related]
3. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
[TBL] [Abstract][Full Text] [Related]
4. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
5. Development and Clinical Applications of Antisense Oligonucleotide Gapmers.
Chan L; Yokota T
Methods Mol Biol; 2020; 2176():21-47. PubMed ID: 32865780
[TBL] [Abstract][Full Text] [Related]
6. Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients.
van Roon-Mom WMC; Roos RAC; de Bot ST
Nucleic Acid Ther; 2018 Apr; 28(2):59-62. PubMed ID: 29620999
[TBL] [Abstract][Full Text] [Related]
7. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
[TBL] [Abstract][Full Text] [Related]
8. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
[TBL] [Abstract][Full Text] [Related]
9. Targeting Huntingtin Expression in Patients with Huntington's Disease.
Tabrizi SJ; Leavitt BR; Landwehrmeyer GB; Wild EJ; Saft C; Barker RA; Blair NF; Craufurd D; Priller J; Rickards H; Rosser A; Kordasiewicz HB; Czech C; Swayze EE; Norris DA; Baumann T; Gerlach I; Schobel SA; Paz E; Smith AV; Bennett CF; Lane RM;
N Engl J Med; 2019 Jun; 380(24):2307-2316. PubMed ID: 31059641
[TBL] [Abstract][Full Text] [Related]
10. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.
Tabrizi SJ; Estevez-Fraga C; van Roon-Mom WMC; Flower MD; Scahill RI; Wild EJ; Muñoz-Sanjuan I; Sampaio C; Rosser AE; Leavitt BR
Lancet Neurol; 2022 Jul; 21(7):645-658. PubMed ID: 35716694
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.
Dash D; Mestre TA
Neurotherapeutics; 2020 Oct; 17(4):1645-1659. PubMed ID: 32705582
[TBL] [Abstract][Full Text] [Related]
12. Nucleic Acid Therapeutics in Huntington's Disease.
Singh K; Roy I
Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
[TBL] [Abstract][Full Text] [Related]
13. Knocking Down Long Noncoding RNAs Using Antisense Oligonucleotide Gapmers.
Maruyama R; Yokota T
Methods Mol Biol; 2020; 2176():49-56. PubMed ID: 32865781
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies for Huntington's disease.
Estevez-Fraga C; Flower MD; Tabrizi SJ
Curr Opin Neurol; 2020 Aug; 33(4):508-518. PubMed ID: 32657893
[TBL] [Abstract][Full Text] [Related]
15. [Hope for Huntington's disease patients: first clinical gene silencing study in progress].
Rollnik JD
Fortschr Neurol Psychiatr; 2017 Aug; 85(8):463-466. PubMed ID: 28841744
[TBL] [Abstract][Full Text] [Related]
16. Oligonucleotides Targeting DNA Repeats Downregulate
Umek T; Olsson T; Gissberg O; Saher O; Zaghloul EM; Lundin KE; Wengel J; Hanse E; Zetterberg H; Vizlin-Hodzic D; Smith CIE; Zain R
Nucleic Acid Ther; 2021 Dec; 31(6):443-456. PubMed ID: 34520257
[TBL] [Abstract][Full Text] [Related]
17. Is Huntington's disease on the threshold of a new era in treatment?
Sandy S; Richard A
Neurodegener Dis Manag; 2019 Oct; 9(5):255-258. PubMed ID: 31580228
[No Abstract] [Full Text] [Related]
18. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
19. Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks.
Leavitt BR; Kordasiewicz HB; Schobel SA
JAMA Neurol; 2020 Jun; 77(6):764-772. PubMed ID: 32202594
[TBL] [Abstract][Full Text] [Related]
20. [Gene-selective treatment approaches for Huntington's disease].
Mühlbäck A; Lindenberg KS; Saft C; Priller J; Landwehrmeyer GB
Nervenarzt; 2020 Apr; 91(4):303-311. PubMed ID: 32179957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
